Mometasone furoate and fluticasone furoate are equally effective in restoring nasal epithelial barrier dysfunction in allergic rhinitis.
Allergic rhinitis
Epithelial integrity
Fluticasone furoate
Mometasone furoate
Tight junctions
Journal
The World Allergy Organization journal
ISSN: 1939-4551
Titre abrégé: World Allergy Organ J
Pays: United States
ID NLM: 101481283
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
08
03
2021
revised:
27
07
2021
accepted:
25
08
2021
entrez:
27
9
2021
pubmed:
28
9
2021
medline:
28
9
2021
Statut:
epublish
Résumé
Tight junction defects (TJ) have been associated with a defective epithelial barrier function in allergic rhinitis (AR). Intranasal corticosteroids are potent drugs frequently used to treat AR and are shown to restore epithelial integrity by acting on TJs and by reducing type 2 cytokine production. However, the effect of different classes of intranasal corticosteroids on the epithelial barrier has not been studied. Therefore, we compared the effect of 2 intranasal corticosteroids, ie, fluticasone furoate (FF) and mometasone furoate (MF) on epithelial barrier function. Both FF and MF similarly increased trans-epithelial electrical resistance of primary nasal epithelial cell cultures from AR patients. In a house dust mite-induced allergic asthma mouse model, FF and MF had similar beneficial effects on fluorescein isothiocyanate-dextran 4 kDa mucosal permeability, eosinophilic infiltration and IL-13 levels. Both molecules increased mRNA expression of the TJ proteins occludin and zonula occludens-1, thereby restoring epithelial barrier function. Lastly, we showed that long-term FF treatment also increased expression of occludin in AR patients compared to controls. In conclusion, both FF and MF effectively restore epithelial barrier function by increasing expression of TJ proteins in AR patients.
Identifiants
pubmed: 34567350
doi: 10.1016/j.waojou.2021.100585
pii: S1939-4551(21)00079-X
pmc: PMC8436167
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100585Informations de copyright
© 2021 Published by Elsevier Inc. on behalf of World Allergy Organization.
Déclaration de conflit d'intérêts
The authors declare no competing interest in relation to this research.
Références
Lancet. 2011 Dec 17;378(9809):2112-22
pubmed: 21783242
Am J Respir Cell Mol Biol. 2016 May;54(5):707-17
pubmed: 26473470
J Allergy Clin Immunol. 2016 Apr;137(4):1043-1053.e5
pubmed: 26846377
Int Immunopharmacol. 2012 Feb;12(2):350-7
pubmed: 22210372
Tissue Barriers. 2013 Apr 1;1(2):e24333
pubmed: 24665390
PLoS One. 2015 May 01;10(5):e0123163
pubmed: 25932636
J Allergy Clin Immunol. 2011 Sep;128(3):549-56.e1-12
pubmed: 21752437
Am J Rhinol Allergy. 2012 Jan-Feb;26(1):36-44
pubmed: 22391079
Clin Immunol. 2014 Nov;155(1):126-135
pubmed: 25236785
J Allergy Clin Immunol. 2020 Jun;145(6):1499-1509
pubmed: 32507228
Ann Allergy Asthma Immunol. 2008 Mar;100(3):264-71
pubmed: 18426147
Clin Exp Allergy. 2011 Feb;41(2):160-70
pubmed: 21121980
South Med J. 2007 Jul;100(7):701-8
pubmed: 17639750
Allergy. 2020 May;75(5):1155-1164
pubmed: 31769882